Prognostic model for high-tumor-burden follicular lymphoma integrating baseline and end-induction PET: a LYSA/FIL study
| Autor: | Corinne Haioun, Judith Trotman, Gilles Salles, Stefano Luminari, Loïc Chartier, Hervé Tilly, Michel Meignan, Rene-Olivier Casasnovas, Jehan Dupuis, Massimo Menga, Vittoria Tarantino, Annibale Versari, Massimo Federico, Alina Berriolo-Riedinger, Anne-Ségolène Cottereau |
|---|---|
| Přispěvatelé: | Hôpital Henri Mondor, Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 ( UPEC UP12 ), Service de médecine nucléaire [AP-HP Hôpital Cochin], CHU Cochin [AP-HP], IRCCS-Arcispedale Santa Maria Nuova, Reggio Emilia, Institut de Mathématiques de Toulouse UMR5219 ( IMT ), Centre National de la Recherche Scientifique ( CNRS ) -Institut National des Sciences Appliquées - Toulouse ( INSA Toulouse ), Institut National des Sciences Appliquées ( INSA ) -Institut National des Sciences Appliquées ( INSA ) -PRES Université de Toulouse-Université Paul Sabatier - Toulouse 3 ( UPS ) -Université Toulouse - Jean Jaurès ( UT2J ) -Université Toulouse 1 Capitole ( UT1 ), Epidémiologie des Maladies Emergentes, Conservatoire National des Arts et Métiers [CNAM] ( CNAM ) -Institut Pasteur [Paris]-Pasteur-Cnam risques infectieux et émergents ( PACRI ), Institut Pasteur [Paris]-Conservatoire National des Arts et Métiers [CNAM] : EA4628-Conservatoire National des Arts et Métiers [CNAM] : EA4628, Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand ( CHU Dijon ), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Service d'hématologie clinique, Groupe d'étude des proliférations lymphoïdes ( GPL ), Université de Rouen Normandie ( UNIROUEN ), Normandie Université ( NU ) -Normandie Université ( NU ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), Department of Oncology and Hematology, University of Modena and Reggio Emilia, Centre Hospitalier Lyon Sud [CHU - HCL] ( CHLS ), Hospices Civils de Lyon ( HCL ), Concord Repatriation General Hospital, Service de médecine nucléaire [Créteil], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Henri Mondor-Université Paris-Est Créteil Val-de-Marne - Paris 12 (UPEC UP12), Institut de Mathématiques de Toulouse UMR5219 (IMT), Université Toulouse 1 Capitole (UT1)-Université Toulouse - Jean Jaurès (UT2J)-Université Toulouse III - Paul Sabatier (UPS), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-PRES Université de Toulouse-Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS), Centre Hospitalier Lyon Sud [CHU - HCL] (CHLS), Hospices Civils de Lyon (HCL), Centre Hospitalier Universitaire de Dijon - Hôpital François Mitterrand (CHU Dijon), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), Groupe d'étude des proliférations lymphoïdes (GPL), Université de Rouen Normandie (UNIROUEN), Normandie Université (NU)-Normandie Université (NU)-Institut National de la Santé et de la Recherche Médicale (INSERM), Università degli Studi di Modena e Reggio Emilia (UNIMORE) |
| Jazyk: | angličtina |
| Rok vydání: | 2018 |
| Předmět: |
Male
0301 basic medicine Oncology medicine.medical_specialty Biochemistry Immunology Hematology Cell Biology Population Follicular lymphoma [SDV.CAN]Life Sciences [q-bio]/Cancer Models Biological Disease-Free Survival [ SDV.CAN ] Life Sciences [q-bio]/Cancer 03 medical and health sciences 0302 clinical medicine Median follow-up Internal medicine medicine Humans Prospective Studies Risk factor education Prospective cohort study Lymphoma Follicular Aged education.field_of_study business.industry Hazard ratio Middle Aged Prognosis medicine.disease Confidence interval Tumor Burden Lymphoma 030104 developmental biology Positron-Emission Tomography 030220 oncology & carcinogenesis Multivariate Analysis Disease Progression Female business |
| Zdroj: | Blood Blood, American Society of Hematology, 2018, 131 (22), pp.2449-2453. 〈10.1182/blood-2017-11-816298〉 Blood, American Society of Hematology, 2018, 131 (22), pp.2449-2453. ⟨10.1182/blood-2017-11-816298⟩ |
| ISSN: | 0006-4971 1528-0020 |
| Popis: | International audience; Both total metabolic tumor volume (TMTV), computed on baseline positron emission tomography (PET), and end of induction (EOI) PET are imaging biomarkers showing promise for early risk stratification in patients with high-tumor-burden follicular lymphoma. A model was built incorporating these 2 factors in 159 patients from three prospective trials: 2 Lymphoma Study Association (LYSA) studies and 1 Fondazione Italiana Linfomi (FIL) trial. Median follow up was 64 months. High TMTV (>510 cm3) and positive EOI PET were independent, significant risk factors for progression. Their combination stratified the population into 3 risk groups: patients with no risk factors (n = 102; 64%) had a 5-year progression-free survival (PFS) of 67% vs 33% (hazard ratio [HR], 2.9; 95% confidence interval [CI], 1.8-4.9) for patients with 1 risk factor (n = 44; 27%) and only 23% (HR, 4.6; 95% CI, 2.3-9.2) for patients with both risk factors (n = 13; 8%). 2-year PFS was respectively 90% vs 61% (HR, 4.8; 95% CI, 2.2-10.4) and 46% (HR, 8.1; 95%CI, 3.1-21.3). This model enhances the prognostic value of PET staging and response assessment, identifying a subset of patients with a very high risk of progression and early treatment failure at 2 years. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|